This clinical trial is focused on studying a treatment for unresectable metastatic colorectal cancer, which is a type of cancer that has spread beyond the colon and cannot be removed with surgery. The treatment being tested involves a medication called Avastin, which contains the active substance bevacizumab. Bevacizumab is a type of protein that helps to slow the growth of new blood vessels that tumors need to grow. In this study, the effect of increasing the dose of Avastin will be evaluated in patients who are receiving it as part of their first-line treatment for this type of cancer.
The purpose of the study is to see if adjusting the dose of Avastin can improve the time patients live without their cancer getting worse, known as progression-free survival. Participants in the study will receive Avastin through an intravenous infusion, which means the medication is given directly into a vein. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will be conducted over a period of time, with regular check-ups and assessments to monitor the patients’ health and the cancer’s response to the treatment.
Throughout the study, researchers will also look at other important factors, such as the overall survival of patients, the safety of the treatment, and any side effects that may occur. They will also assess the quality of life of participants and conduct a medical-economic analysis to understand the cost-effectiveness of the treatment. This trial aims to provide valuable information on whether adjusting the dose of Avastin can offer better outcomes for patients with this challenging form of cancer.
France 
